| Date | Title | Link |
|---|---|---|
| 2022 | CAR-T engager proteins for the treatment of B cell cancers – AACR 2022 | View PDF |
| 2022 | CARs and CAR-T Engager Proteins Targeting Multiple Antigens for Acute Myeloid Leukemia and Multiple Myeloma – ASGCT 2022 | View PDF |
| 2021 | Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors – SITC 2021 | View PDF |
| 2021 | Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy – ASH 2021 | View PDF |
| 2021 | Anti-CD19 CAR T cells potently redirected to kill solid tumor cells – Plos One 2021 | View PDF |
| 2021 | Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo – Molecular Cancer Therapeutics 2021 | View PDF |
| 2020 | A Novel Platform For Cell Therapeutics – OCTS July 2020 | View Article |
| 2020 | Development of novel CAR T engager proteins for cell therapies that target metastatic and primary CNS malignancies – SITC 2020 | View PDF |
| 2020 | One CAR to Rule Them all – the Exemplary Fitness of CAR-CD19 T Cells and Their Repurposing for the Eradication of Solid Tumors – ASGCT 2020 | View PDF |
| 2019 | A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo – ASH 2019 #252 | View PDF |
| 2019 | Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design – Biochemistry. 2019 | View Article |
| 2019 | Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins – Mol Pharm. 2019 | View Article |
| 2018 | CAR19 T cells secreting antigen-retargeting fusion proteins have remarkable potency against diverse tumor types – AACR 2018 #2569 | View PDF |
| 2018 | Hijacking CAR19 T cells to target diverse hematologic and solid tumors – SITC 2018 #267 | View PDF |
| 2017 | CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors – AACR 2017 #3768 | View PDF |
| 2017 | CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies – ASH 2017 #4457 | View PDF |
Aleta BioTherapeutics
Developing unique cell therapy solutions for all cancers.
